However, despite the heterozygous CDKN2A P16WT/G101W/P14WT/R115L germline variant, cell cycle checkpoints were still activated upon KRASG12Dexpression, posing a potentially relevant tumor progression barrier. This evidence concerns the gene CDKN2A and neoplasm.